Pressmeddelande -
Scandinavian Biopharma announces marketing and distribution agreement with Emergent to relaunch the oral typhoid vaccine (Ty21a) in Germany
Scandinavian Biopharma has expanded the partnership with Emergent Travel Health Inc. to also include the marketing and distribution of Emergent’s oral typhoid vaccine (Ty21a) in Germany.
Emergents oral typhoid vaccine will complement and strengthen Scandinavian Biopharma´s commercial portfolio by leveraging its existing marketing and distribution network in Germany. Due to the travel restrictions during the Covid-19 pandemic the vaccine has not been available in Germany since the first half of 2020. In May 2022 the vaccine was successfully re-launched in the German market.
Björn Sjöstrand, CEO of Scandinavian Biopharma, commented: “We are pleased to expand our commercial footprint in the largest EU market by adding a complementary product to our existing product portfolio. We are really excited to be able to bring back this unique typhoid vaccine to the German market.”
Ämnen
Kategorier
Scandinavian Biopharma
We are a research-based specialty biopharma company determined to give people worldwide a longer and better life. We are developing the first vaccine for protection against diarrhoea caused by ETEC in both travellers and endemic populations. We distribute a wide range of specialty biopharma products with focus on vaccines and immunoglobulins.
